ESTRADIOL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Osta kohe

Laadi alla Toote omadused (SPC)
25-10-2022

Toimeaine:

ESTRADIOL

Saadav alates:

PHARMASCIENCE INC

ATC kood:

G03CA03

INN (Rahvusvaheline Nimetus):

ESTRADIOL

Annus:

1MG

Ravimvorm:

TABLET

Koostis:

ESTRADIOL 1MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

ESTROGENS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0106457003; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2022-10-26

Toote omadused

                                _ _
_ESTRADIOL (17β-estradiol) _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ESTRADIOL
17β-estradiol Tablets
Tablets 0.5 mg, 1 mg, 2 mg
USP
Estrogen
Pharmascience Inc.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
Canada H4P 2T4
www.pharmascience.com
Date of Initial Authorization:
OCT 25, 2022
Submission Control Number: 267798
_ _
_ _
_ESTRADIOL (17β-estradiol) _
_Page 2 of 32_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
..............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
......................................................... 6
4.5
Missed Dose
..............................................................................................................
6
5
OVERDOSAGE
.............................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
..............
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Toote omadused Toote omadused prantsuse 25-10-2022

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu